Change in the leadership at Novartis Pharma Switzerland AG, Bern

02-Apr-2001

In April 1996 Dr. Martin Batzer was appointed Head of the former Sandoz-Wander Pharma AG in Bern and was immediately plunged into the great task of merging the Swiss pharma affiliates of Sandoz and Ciba to create the present Novartis Pharma Switzerland AG. After five years' service in Bern, Martin Batzer will now take up the newly created post of Head of Pharma Affairs in Basel at the beginning of April. As member of the board of pharma management worldwide he will be in charge of the central services in Basel and, in addition, have global responsibility for patents, pharma policy, pricing policy and central purchasing.

The new chief executive of Novartis Pharma Switzerland AG will be Armin Zust, the present national head of Novartis Farmacéutica Mexico. Before being named Head of the Novartis Farmacéutica Mexico in 1992 he had a numer of responsabilities for Novartis in Brazil and Colombia. Armin Zust, a Swiss national, started his career with Roche – first in Basel and later in Nigeria.

Novartis Pharma Switzerland AG, a subsidiary of Novartis Pharma AG in Basel, is responsible for Novartis prescription medicines sold in Switzerland in the business sectors primary care, ophthalmology, transplantation, oncology, central nervous system, mature products and generic medicines. It has approximately 210 employees, engaged in the fields of clinical research, marketing, sales, and in scientific documentation and drug registration. Further information is available on the internet under http://www.pharma.ch.novartis.com.

https://www.chemeurope.com/en/news/2295/change-in-the-leadership-at-novartis-pharma-switzerland-ag-bern.html